---
title: "Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286456184.md"
description: "Telomir Pharmaceuticals, Inc. reported a net loss of $(990,947) with no revenue for Q1 2026, an improvement from a $(2,179,828) loss in Q1 2025. Diluted EPS was $(0.03), better than $(0.07) a year earlier. The FDA cleared an IND for Telomir-1 to begin trials for advanced triple-negative breast cancer. A merger with TELI consolidated global rights to Telomir-1. Bayshore Trust committed up to $5.0M for funding, with $1.0M tied to IND acceptance. Cash is sufficient to fund operations into Q1 2027."
datetime: "2026-05-14T19:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286456184.md)
  - [en](https://longbridge.com/en/news/286456184.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286456184.md)
---

# Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary

Telomir Pharmaceuticals, Inc. reported a first-quarter 2026 net loss of $(990,947) and no revenue as the company continues preclinical and early clinical preparations; diluted loss per share was $(0.03), improved from $(0.07) a year earlier, and cash is sufficient to fund operations into Q1 2027.

**Financial Highlights**

-   Revenue was $0 for Q1 2026, unchanged from $0 in the year-ago quarter.
-   Net income was a loss of $(990,947) for Q1 2026, compared with a loss of $(2,179,828) in Q1 2025 (loss narrowed by 54.5%).
-   Diluted EPS was a loss of $(0.03) for Q1 2026, compared with $(0.07) in Q1 2025.

**Business Highlights**

-   Clinical milestone: The FDA cleared an IND for Telomir-1 (Telomir‑Zn) to begin a trial in advanced/metastatic triple-negative breast cancer (TNBC).
-   Pipeline consolidation: A merger with TELI unified global rights to Telomir‑1, simplifying development and potential commercialization.
-   Capital & development funding: Bayshore Trust committed up to $5.0M, with $1.0M provided tied to IND acceptance and the start of a Phase 1/2 trial.
-   R&D progress: Increased research and development spending and ongoing preclinical work to prepare for clinical trials across multiple indications.
-   Operational runway: Reported cash supports operations into Q1 2027, enabling near-term clinical and regulatory activities.

Original SEC Filing: Telomir Pharmaceuticals, Inc. \[ TELO \] - 10-Q - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TELO.US](https://longbridge.com/en/quote/TELO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Telomir Reports Peer-Reviewed Preclinical Telomir-Zn Data Showing Dose-Dependent Survival & Reduced Hepatic Copper](https://longbridge.com/en/news/287061178.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)